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ABSTRACT
Insulin represents a mainstay of glucose-lower-
ing therapy for many adults with type 2 dia-
betes mellitus (T2DM). Insulin treatments
prescribed as standard care for the majority of
people with T2DM, such as basal human insu-
lin, may not be optimal in the treatment of frail
older adults because of the increased demand
on health care staff to administer multiple daily
injections and monitor the patient. When
choosing an insulin regimen for a frail older
person with T2DM, predictability of glucose
lowering effect, risk of hypoglycaemia, ease of
administration, and simplicity and flexibility of
dosing are major determining factors. Multiple
daily injections may be too complex for older
frail adults, whilst providing an unnecessary
degree of tight glycaemic control and low doses
of once-daily basal insulin analogues such as
insulin degludec may be a reasonable option as
cognitive decline or functional disability
increases. Although insulin degludec has a
substantially higher acquisition cost than rou-
tinely used basal human insulin, it has a longer,
more predictable pharmacological profile and is
more amenable to once-daily administration,
translating into a reduced burden of care and
potential cost savings for insulin-treated frail
older adults. Insulin acquisition cost represents
only a small proportion of the total cost of
treatment, and it is important to consider the
value perspective of insulin therapy in frail
older adults from all stakeholders in the health
care system.
Keywords: Frail elderly; Health care costs;
Human insulin; Insulin analogue; Insulin
degludec; Type 2 diabetes mellitus
W. D. Strain (&)
Diabetes and Vascular Research Centre, University
of Exeter Medical School, and the Academic
Department of Healthcare for Older Adults, Royal
Devon & Exeter Hospital, Exeter, UK
e-mail: d.strain@exeter.ac.uk
A. R. Morgan
Health Economics and Outcomes Research Ltd.,
Cardiff, UK
M. Evans





There are several different insulin
treatment options for type 2 diabetes in
older adults; however, current available
treatment strategies are derived from
findings in younger adults that do not
commonly present with the issues
associated with frailty and age, such as
cognitive impairment and the presence of
physical disabilities.
The presence of frailty, functional
impairments, and cognitive decline in
older adults with type 2 diabetes
highlights the importance of community
nursing support for insulin
administration.
The protracted duration of insulin
degludec facilitates flexible dosing and
convenience with once-daily
administration, translating into clinical
and economic value, particularly in frail
older adults.
Although insulin degludec has a
substantially higher acquisition cost than
basal human insulin, when considering
the value of insulin, it is important to
include insulin resource use beyond
acquisition costs and, in particular,
potential health care service use.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) represents a
major health burden for older adults, with
prevalence increasing with age (Fig. 1). It affects
one in five people[65 years old (135.6 million
people worldwide) [1], and this number is
expected to increase dramatically in the future
with the global burden of T2DM in individu-
als C 65 years projected to reach 276.2 million
by 2045 [1]. In addition to the usual complica-
tions of diabetes, the older population with
diabetes also has a higher risk of other condi-
tions such as falls and fractures, depression,
physical disability, pain, polypharmacy due to
co-morbidities, and urinary incontinence
(Fig. 2). Therefore, the management of diabetes
in these older adults demands different treat-
ment strategies dependent on the presence or
absence of comorbidities as well as on the
patients’ living situation and available
resources.
Whilst the majority of older adults with
T2DM are high functioning, medically stable,
and able to perform self-care, diabetes can
reduce physical functioning [2]. Sarcopenia
(age-related muscle loss associated with reduced
power) is a newly emerging and high-impact
complication of T2DM in older adults [3, 4],
with a prevalence in the range of 7–29% in
different populations [5]. Sarcopenia leads to
frailty, a condition in which an individual has
decreased physical reserves [6], and is usually
defined based on the presence of three or more
of the following: unintentional weight loss, self-
reported exhaustion, weakness, slow walking
speed, and low physical activity [7]. Further-
more, T2DM has been consistently associated
with an increased risk of cognitive decline,
including Alzheimer’s disease and vascular
dementia [8–10], and compared to people
without diabetes, individuals with diabetes
have a greater rate of cognitive decline [11]. As
the decline in cognitive function continues,
older people with diabetes and dementia are
Fig. 1 Prevalence of diabetes by age group in England and
Wales [44]
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liable to struggle to follow complex treatment
regimens. The consequences of a mistake in self-
medication of diabetes treatments can be dev-
astating; missed doses can result in a hyperos-
molar hyperglycaemic state, or diabetic
ketoacidosis in those with insulin deficiency,
whereas excess dosing can lead to devastating
hypoglycaemia. As a result, when cognitive
decline ensues, these individuals often require
considerable support from both health care and
social care practitioners in diabetes manage-
ment, including treatment administration.
Consequently, the treatment of T2DM and its
complications in older adults represents a sig-
nificant cost to the NHS with approximately
61% of all health care costs attributed to T2DM
being incurred by people with T2DM who are[
65 years of age [12]. With this in mind, it is
imperative to optimise the clinical and eco-
nomic value with respect to treatment regimens
in the population of frail older adults with
T2DM.
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
INSULIN TREATMENT IN FRAIL
OLDER ADULTS WITH T2DM
T2DM treatments in frail older adults need to be
carefully prescribed and monitored, taking into
consideration the patient cognitive capacities,
presence of other comorbidities, cardiovascular
risk, and importance of avoiding hypogly-
caemia. Although there are several different
treatment options for older adults with T2DM,
these treatment strategies are based on trial data
in younger adults that do not commonly pre-
sent with the issues associated with frailty and
age. Despite the recommendations of interna-
tional regulatory agencies to include a wide
range of patients with T2DM, exclusion of older
individuals from ongoing trials regarding T2DM
is frequent [13]. This exclusion limits the level
of evidence that clinicians require when treat-
ing frail older adults with T2DM. In the absence
of clear clinical data, guidance is often based on
expert consensus [14, 15].
Current treatment recommendations for frail
older adults are limited to dipeptidyl peptidase-
4 (DPP-4) inhibitors, which have limited effi-
cacy sodium-glucose co-transporter-2 (SGLT2)
inhibitors for those with heart failure, and
insulin [15]. Although there are many different
approaches to insulin initiation, in many health
care systems use of a basal insulin is the pre-
ferred approach to commencing insulin therapy
in people with T2DM. The action profile of
human basal insulin peaks within a few hours of
administration, translating into a potential
increased risk of hypoglycaemia, and in partic-
ular nocturnal hypoglycaemia if human insulin
is administered in the evening. By contrast,
insulin analogues provide slower, more pro-
longed absorption rates and a relatively con-
stant pharmacokinetic/pharmacodynamic (PK/
PD) 24 h profile [16], reducing the potential of
hypoglycaemia and furthermore offering the
potential for more predictable once-daily dos-
ing [17].
Insulin degludec is a basal insulin analogue
with an ultra-long duration of action. This
ultra-long duration of action, as well as the low
variability in glucose-lowering activity of insu-
lin degludec, has translated into real clinical
Fig. 2 Comorbidities in older adults with diabetes
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benefits, in particular a reduced risk of hypo-
glycaemic events [18, 19].
Furthermore, the pharmacokinetic profile
and protracted half-life of insulin degludec
render this insulin a truly once-daily insulin
and enables the potential for flexible dosing
with a time interval of between 8 and 40 h
without comprising its efficacy or safety profile.
This dosing flexibility is particularly relevant
when considering frail older adults that require
assistance with insulin administration from a
health care worker, carer, or relative. Conse-
quently, even though there are limited data
related to insulin degludec, or indeed any
insulin, in frail older adults, the pharmacoki-
netic profile, greater convenience, and less
variable glycaemic control render insulin
degludec a very appealing therapy option for
insulin administration in frail older adults.
CLINICAL EFFICACY OF INSULIN
DEGLUDEC FOR TREATING FRAIL
OLDER ADULTS WITH T2DM
The ultra-long-acting insulin degludec with
reduced intra- and inter-individual variability in
time-action profiles compared with other insu-
lins can provide a more stable glucose-lowering
action and improved PK/PD profile, which
translates clinically into a reduced risk of
hypoglycaemia [20]. Reduced risks of hypogly-
caemia have been observed with insulin deglu-
dec across age groups including older adults.
The results of a meta-analysis of pooled patient-
level data in older adults C 65 years from five
BEGIN trials involving patients with T2DM
[18, 19, 21–23] demonstrated 24% and 36%
lower estimated rates of overall hypoglycaemia
and nocturnal hypoglycaemia, respectively,
with insulin degludec compared to insulin
glargine [24]. The hypoglycaemic benefits
demonstrated with insulin degludec in older
adults were consistent with those seen in the
full adult patient population [25]. A post hoc
analysis of data from the SWITCH 2 trial
demonstrated that treatment with insulin
degludec lowered the rates of overall severe and
blood glucose-confirmed symptomatic hypo-
glycaemia by 30% and 31% versus insulin glar-
gine in individuals aged[65 years
and B 65 years, respectively. The reduction in
the rate of nocturnal symptomatic hypogly-
caemia or blood glucose-confirmed symp-
tomatic hypoglycaemia with insulin degludec
versus insulin glargine was 41 and 43%,
respectively, in individuals aged[65 years
and B 65 years [26]. The reduced risk of hypo-
glycaemia with insulin degludec compared to
glargine across the age groups was consistent
with post hoc analysis of data from the DEVOTE
trial, which also demonstrated that patients
randomised to insulin degludec had a lower risk
of severe hypoglycaemia and nocturnal hypo-
glycaemia compared to those randomised to
insulin glargine across age groups (50–64 and
65–74 years), although a non-significant trend
was demonstrated in patients aged C 75 years
[27]. In addition, the cardiovascular safety data
of insulin degludec versus glargine were also
observed across age groups [27], which is an
important consideration for clinicians manag-
ing older adults with T2DM in clinical practice,
since this category of patients typically has high
cardiovascular risk.
The reduction in hypoglycaemia is particu-
larly important for frail, older adults with T2DM
as this population is more vulnerable to the
occurrence and consequences of hypogly-
caemia, with episodes of severe hypoglycaemia
in this population having been associated with
increased risk of cardiac autonomic dysfunction
[28], falls [29, 30], and dementia [31] (a 26%
increase in the risk for developing dementia
after a single event with 3 or more ‘events’
increases the risk of dementia by 96% [31]).
Moreover, hypoglycaemia awareness in frail
older adults may be impaired, and as this pop-
ulation often live alone the consequences of
hypoglycaemia can result in significant mor-




FOR TREATING FRAIL OLDER
ADULTS WITH T2DM
As the acquisition cost for insulin degludec is
greater than that of human insulin, many peo-
ple with T2DM are preferentially prescribed
human insulin primarily based on price con-
siderations. However, as people become
increasingly frail, the potential limitations of
basal human insulin are likely to become more
apparent particularly with respect to adminis-
tration, flexibility of dosing, predictability of
the glucose-lowering effect, and risk of hypo-
glycaemia. The dangers of inappropriate
administration and dosing along with the
patient’s ability to appropriately administer
insulin are critical factors that require regular
review and assessment.
As cognitive decline or functional disability
increases, the burden of insulin delivery will
typically pass on to a family member, carer, or
nursing staff. Therefore, when considering
treatment costs, health visitor costs should be
taken into account. A recent report ‘Behind
closed doors? The hidden impact of diabetes in
social care found that there are[70,000 people
in the UK in a social care setting and the direct
care costs of T2DM amount to approximately
£1.4 billion, five times more than is spent on
the drug treatment itself [32].
The introduction of updated clinical guide-
lines for managing T2DM, with less stringent
glycaemic targets for frail older adults [33, 34],
aims to limit the risk of hypoglycaemia. How-
ever, a reduced risk does not negate the burden
of hypoglycaemia completely. Hypoglycaemia
carries a large cost burden as a result of hospi-
talisation for severe episodes [35]. It has been
demonstrated that the occurrence of hypogly-
caemia in older adults is associated with a 36%
increase in diabetes related expenditure [36].
Whilst some of this is in the direct cost of the
hypoglycaemia, a significant proportion of this
is based on the increased risk of complications
such as stroke, fractures, and increased use of
social care [37]. Even non-severe hypoglycaemia
can have economic consequences in older
patients as they lose confidence and have
increased dependency on social support [38].
Insulin analogues, with a low risk of hypogly-
caemia, may be preferred in frail older adults
with T2DM, as the drug acquisition cost has the
potential to be offset by the cost saving from
reduced hypoglycaemia-related health care
resource utilisation.
Insulin regimens tend to be either a once- or
twice-daily basal insulin. The latter requires
administration with morning and evening
meals within a relatively narrow time window.
Staffing for the community nursing team can be
a challenge with the team’s core hours between
8 a.m. and 6 p.m. and there being a high
demand for insulin administration around the
start and finish of these core hours. This poses
two challenges, the first is the logistics of
administering the insulin within a short time
window and the second is the cost of the visit
itself in the setting of limited staffing. This has
been exacerbated throughout the Covid-19
pandemic when community staff have been
redeployed and the concerns regarding footfall
and risk of coronavirus spread. Given that the
NHS is currently facing a shortage of resources,
in terms of both costs and the availability of
health care workers to deliver this care, it is vital
to evaluate the economic value, alongside the
clinical efficacy, of different treatment regi-
mens, such as insulin degludec, in frail older
adults with T2DM.
In a UK health care setting, whereby district
nurses in the community met regularly to
review the diabetes patients they attend for
insulin injections and where clinically appro-
priate, based mainly but not wholly on frailty
status, a switch from twice- to a once-daily
insulin regimen was implemented; the daily
visit rate was reduced from 300 to 166 visits (23
patients had their insulin stopped and 121
switched to a once-daily insulin regimen) [39].
Although the cost saving associated with this
initiative has not been reported, a reduction of
134 visits per day, 365 days per year, is likely to
equate to a huge cost reduction.
Insulin degludec has a substantially higher
acquisition cost (£46.60 a month) than rou-
tinely used basal human insulin (i.e., Insulatard,
Humulin; £19.08 per month) [40, 41]. However,
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due to its pharmacological profile, patients
using insulin degludec would only require a
maximum of one nurse visit per day compared
to patients prescribed human insulin, which are
likely to require multiple visits to ensure safe
and optimal insulin dosing, administration, and
monitoring. Furthermore, the biological stabil-
ity when administered from 8 to 40 h apart
increases the flexibility of administration [42], a
notable advantage at times of stress on service,
such as weekends, holidays, and times of sig-
nificant staff pressure such as the Covid-19
pandemic. Consequently, the use of a more
expensive, longer acting insulin that requires
less monitoring and administration may ulti-
mately translate into whole health care system
cost savings when the cost of external assistance
in included (Fig. 3). As the current NHS tariff for
a nurse visit is £30 (based on a 15-min visit for a
band 7 nurse) [43], costs would be expected to
be approximately £900 per month (30-day
month) for degludec visits (once a day) and
£1800 per month for human insulin visits
(twice a day). Consequently, the estimated cost
per month including drug acquisition cost and
treatment administration is £946.60 for insulin
degludec compared to £1819.08 for human
insulin, resulting in a saving of £872.48 per
patient per month (£10,469.76 per year) asso-
ciated with nursing visits alone (in addition to
the use of fewer needles and test strips).
SUMMARY
Insulin remains an important cornerstone of
diabetes management for many frail older
adults with T2DM. Age-related cognitive
impairment and the presence of physical dis-
abilities and other age-related problems, such as
frailty, malnutrition, pain, and depression, may
adversely affect self-care abilities, particularly
around insulin administration, in older frail
adults with T2DM. Consequently, there has
been significant unmet need with respect to
insulin therapy in this population. The
requirement for the simplification of insulin
regimens has been further highlighted over the
past 18 months as a consequence of the Covid-
19 pandemic and the consequent stress this has
placed on all stakeholders in the health care
system including patients, carers, and commu-
nity-based services. There has become a need to
re-evaluate the insulin regimens of people who
require district nursing visits for insulin
administration to reduce contact and therefore
reduce risk of contamination as well as to
address the ever-increasing demand for com-
munity nursing services.
Insulin degludec represents a significant
evolution with respect to insulin therapy in frail
older adults, with the potential for flexible true
once daily dosing that has obvious service
resource utilisation impacts as well as quality of
Fig. 3 Value of insulin degludec
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life benefits for patients as well as their family
members and carers.
It is important to consider value of any
therapy from a multiple stakeholder perspec-
tive, and while insulin degludec may have a
higher acquisition cost compared to basal
human insulin, it has a longer, more pre-
dictable pharmacological profile and is more
amenable to once-daily administration, conse-
quently reducing the burden of care and thus
cost associated with supported insulin admin-
istration. Consequently, from both a clinical
and health economic perspective, insulin
degludec could be considered the basal insulin
of choice in frail older adults with T2DM.
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